Siroxyl

Quick links to important sections

Siroxyl

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Siroxyl

What is Siroxyl? Understanding its Classification and Core Ingredient

Property Description
Active ingredient Carbocysteine (S-Carboxymethyl-L-cysteine)
Form Syrup, Oral Solution, Capsules, Tablets
Pharmacological class Mucolytic Agent
Common use Airway secretions clearance
Origin Synthetic derivative of L-cysteine

Siroxyl is a common trade name for a medicinal product whose sole active ingredient is Carbocysteine. This substance is classified as a Mucolytic Agent. Carbocysteine is a synthetic derivative, specifically an L-cysteine thioether, engineered to act directly on the properties of respiratory secretions. The primary function of this pharmacological class is to manage the structure and viscosity of mucus, rather than simply suppressing a cough. Carbocysteine is recognized for its ability to alter the characteristics of abnormal respiratory mucus.


Composition, Origin, and Available Forms

The active core, Carbocysteine, is typically formulated as a single-active ingredient product for oral administration, distinguishing it from common cough remedies that often combine multiple agents. The medicine is commonly available in several oral dosage forms, including syrup or oral solution in an aqueous base, and also in solid forms like capsules or tablets. The availability of the liquid syrup form is a key characteristic, specifically positioning it as suitable for children and adults who require flexible dosing or have difficulty swallowing tablets.


General Purpose: How Siroxyl Modifies Mucus

The general purpose of Siroxyl is to facilitate airway secretions clearance by targeting the physical properties of thick, excessive phlegm associated with respiratory tract disorders. It achieves this goal by reducing the overall viscosity and stickiness of the mucus. The underlying mechanism involves the breakdown of the sticky, cross-linked glycoprotein structure within the phlegm. This action supports natural respiratory function; this modification leads to improved drainage, supporting conditions where the mucus is excessively tenacious. By making secretions thinner and more fluid, the medicine supports the body's natural ciliary movement and cough reflex, thereby enabling more effective expectoration and leading to relief from chest congestion and improved breathing comfort.

What side effects are possible with Siroxyl?

Possible Side Effects and Safety Information for Siroxyl (Carbocisteine)

Official regulatory documents classify adverse reactions to Siroxyl (Carbocisteine) by frequency and system-organ class. The most frequently reported effects involve the gastrointestinal system.

Frequency Classification Key Adverse Reactions (System-Organ Class)
Uncommon Nausea, vomiting, diarrhoea (Gastrointestinal Disorders)
Rare/Very Rare Headache, dizziness, urinary incontinence, muscle pain, palpitations, shortness of breath, bronchospasm, urticaria, rash (across Nervous System, Musculoskeletal, Cardiac, Respiratory, and Skin/Subcutaneous Disorders)
Not Known Anaphylactic reactions, severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome and erythema multiforme, gastrointestinal bleeding, hypothyroidism (across Immune System, Skin/Subcutaneous, Gastrointestinal, and Endocrine Disorders)

Serious and Clinically Significant Adverse Reactions

The most serious adverse events documented in official regulatory sources include anaphylactic reactions (a severe allergic response), gastrointestinal bleeding, and rare but severe skin conditions such as Stevens-Johnson syndrome and erythema multiforme.

Safety-Related Restrictions and Contraindications

Siroxyl is formally contraindicated in patients with known hypersensitivity to the active substance (Carbocisteine) or any excipients. It is strictly contraindicated in patients with an active peptic ulcer and is advised to be avoided in those with a history of gastro-duodenal ulcer due to the risk of disrupting the gastric mucosal barrier and potential bleeding.

Population-Specific Safety Considerations

This medicine is not recommended for use during pregnancy and lactation as safety has not been established. There are also specific precautions noted for patients with a history of asthma due to the risk of bronchoconstriction, and for patients with or susceptible to transient hypothyroidism.

Overdose and Emergency Response

The regulatory documentation for Siroxyl (Carbocysteine) outlines the expected clinical presentation in situations of overdosage, focusing predominantly on effects within the gastrointestinal system. The most likely manifestations documented following the ingestion of an excessive amount are severe gastrointestinal disturbance, which can include explicit symptoms such as significant nausea, vomiting, and acute epigastric discomfort.

Regulatory authorities mandate that any suspected overdosage constitutes a clear requirement to seek immediate medical attention. This direction requires immediate contact with a healthcare professional or an urgent visit to a hospital casualty department. It is officially advised that the medicine container or label be presented to assist medical staff with crucial information regarding the compound.

The official management strategy is defined as symptomatic and supportive treatment. This standard approach is necessitated because the regulatory record explicitly confirms that no specific antidote is known for Carbocysteine overdosage. Management procedures that may be beneficial, as documented in official prescribing information, include initial interventions like gastric lavage. These actions must be followed by a period of patient observation and close monitoring to stabilize the presented symptoms. The potential for serious adverse events, such as gastrointestinal bleeding, is a further documented event that always requires urgent medical attention.

Therapeutic Uses of Siroxyl

Quick Facts

  • Main Use: Used in the management of acute and chronic respiratory conditions.
  • Therapeutic Action: May support the reduction of sputum thickness.
  • Relief Domain: May offer support for individuals experiencing excessive or tenacious bronchial secretions.

Siroxyl is a therapeutic agent that supports the management of respiratory conditions. Its use is indicated for acute and chronic ailments of the respiratory system that are associated with the production of thick and excessive bronchial secretions. It may offer support in making the sputum less viscous, which can assist the individual in clearance of these secretions through coughing.

Siroxyl may also be considered in the management of specific ear, nose, and throat (ENT) issues, such as chronic sinusitis and certain forms of chronic seromucous otitis, when these conditions are related to issues with phlegm clearance. The product is used as part of a comprehensive therapeutic plan to address these symptoms.

This agent is approved in various global regions for these indications. The decision to use this medication is made by a qualified healthcare professional based on an individual's specific health needs.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Siroxyl — Official Regulatory Information

This section outlines the specific populations for whom the use of Siroxyl is prohibited, restricted, or requires special consideration, based strictly on the regulatory Summary of Product Characteristics (SmPC) or equivalent official documentation.


Eligibility Scope

Population Category Eligibility Status (Official)
Populations for whom use is Contraindicated Hypersensitivity to carbocisteine or any other ingredient; Patients with an evolutionary gastro-duodenal ulcer or a history of one; Patients with Phenylketonuria (for certain formulations containing Phenylalanine).
Age-related Eligibility Rules Infants under one month must not be administered the syrup formulation. High-dose granule formulations are not suitable for children up to 15 years of age.
Pregnancy and Lactation Use not recommended due to safety not being established, as per official documentation.
Condition-specific Restrictions Use is prohibited in active or historical gastro-duodenal ulcer conditions.

Eligibility Classifications (High-Level)

Official documents define use restrictions based on established risks to the patient population. Contraindicated use signifies that the risk outweighs any potential benefit. The designation 'not recommended' for pregnancy and lactation indicates that official safety studies were insufficient to confirm safe use during these periods.


Official Eligibility Statements

  • The drug is formally contraindicated in cases of known hypersensitivity to the active substance, carbocisteine, or excipients.
  • Use is strictly prohibited in patients with current or past gastro-duodenal ulcers to prevent complications.
  • The use in infants under one month is formally prohibited due to safety and developmental considerations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Carbocysteine, the active ingredient in Siroxyl, has a limited number of formally documented interaction patterns established in official government regulatory documents. The product’s interaction profile is primarily defined by pharmacodynamic considerations, rather than metabolic mechanisms.

Classification Documented Interaction Pattern
Prohibited Combinations Co-administration is formally noted as irrational with antitussive medicinal products and other agents that are indicated to dry respiratory secretions (e.g., anticholinergics). This restriction is in place because these medicines antagonize the mucolytic's intended function of facilitating the clearance of secretions via productive cough.
Pharmacodynamic Caution Use with caution is advised when co-administering with other medicinal products known to increase the risk of gastrointestinal (GI) bleeding or ulceration. This risk is additive and includes agents such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and corticosteroids.

Official regulatory prescribing information often reports that there are no known or no reported interactions involving common pharmacokinetic mechanisms, such as those mediated by Cytochrome P450 enzymes. The cautionary note regarding the additive risk of GI bleeding is specifically highlighted for elderly patients. Additionally, some liquid formulations contain ethanol as a pharmaceutical excipient, which is documented in the product specifications.

Mechanism of Action

Direct Mucolytic Action and Rheology Modulation

Carbocysteine mediates the cleavage of disulfide bonds (S-S bonds) within the tenacious mucin glycoproteins that form the structural network of pathological mucus. This targeted depolymerization directly reduces the viscosity and elasticity of the secretions. This functional change facilitates the operation of the body's mucociliary clearance apparatus, enabling secretion transport.


Mucoregulatory Effects and Compositional Shift

Beyond physically thinning existing mucus, the molecule modulates the biosynthetic pathways within airway secretory cells. It influences enzymes like sialyltransferase, shifting the profile of newly produced mucus by increasing the proportion of low-viscosity sialomucins relative to high-viscosity fucomucins. This compositional shift results in the secretion of mucus with inherently reduced viscoelasticity, maintaining the adjusted rheological profile over continued synthesis.


️ Cytoprotection via Antioxidant Signaling

Carbocysteine exerts a secondary, protective effect by acting as a scavenger for harmful Reactive Oxygen Species (ROS) prevalent in inflamed airways. This antioxidant activity is linked to the suppression of the NF-κB signaling pathway. This action helps modulate the inflammatory signaling cascade and reduces the oxidative stress-driven stimulus for mucus hypersecretion.

Dosage and Administration Information

Siroxyl (Carbocysteine) is administered exclusively via the oral route, available in both liquid (syrup or oral solution, typically 250 mg/5 mL) and solid (hard capsules, typically 375 mg or 750 mg) forms. Its use is governed by a specific, two-tiered dosing regimen.

Standard Dosing Protocol for Adults

The initial daily dosage for adults and the elderly is 2,250 mg, administered in divided doses, typically three times per day. This initial regimen is sustained until a satisfactory response is achieved. Once favorable results are noted, the dose is reduced to a maintenance daily dose of 1,500 mg in divided doses, usually two or three times daily.

Administration and Constraints

Liquid preparations (syrup/oral solution) require precise measurement using a dedicated dosing cup or syringe supplied with the product to ensure dose accuracy. The medicine can generally be taken without regard to food.

Administration is strictly contraindicated in children under 2 years of age. Combining Siroxyl with antitussive (cough-suppressant) medicinal products is avoided, as this functionally constrains the clearance process intended by the medicine. Treatment for acute conditions is typically short-term, though chronic management may involve longer courses requiring regular clinical review.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Siroxyl


Evidence for Use in Acute Respiratory Conditions

Research exploring the use of Siroxyl for temporary, acute respiratory tract conditions (such as short-term bronchitis) focuses on situations associated with thick mucus, primarily involving short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time. Studies monitored changes in patient-reported outcomes describing perceived discomfort, such as cough severity, and examined the physical characteristics of the mucus itself. Findings describe patterns observed in the studies regarding a shift in the viscosity of the phlegm during the treatment period. However, information on the long-term effects on the overall course of the acute infection remains limited.


Evidence for Use in Chronic Respiratory Conditions

For chronic respiratory conditions, such as Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis, the research scope involves long-term RCTs and systematic reviews that span several months, where the substance was evaluated. The studies monitored key functional outcomes, primarily focusing on the frequency of acute exacerbations (flare-ups) over a one-year period. Findings indicate that in certain patient subgroups, studies described patterns of observations related to the frequency or severity of acute episodes. Despite the longer-term nature of some trials, long-term effects are not fully established regarding critical outcomes like hospitalization rates or mortality.


Unanswered Questions and Research Gaps

Follow-up durations were limited for many important chronic outcomes, meaning the long-term effects of daily use on disease progression are not fully established. Evidence quality varies across studies, with a tendency toward modest sample sizes in the smaller-scale acute and ENT trials. Some studies find patterns related to patient-reported symptoms, but the evidence for major, objective clinical endpoints—such as significant changes in hospitalization rates or survival metrics—is either still emerging or not consistently available across the evidence base.

Key Studies & References Carbocisteine as Adjuvant Therapy in Acute Respiratory Tract Infections in Patients without Underlying Chronic Conditions: Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Siroxyl (FAQ)

Q: How quickly should someone expect to feel the effects of Siroxyl?

A: According to official pharmacokinetic data, the active ingredient in Siroxyl is absorbed relatively quickly after being taken orally. Studies indicate that the concentration of the active substance in the blood typically reaches its peak within 1 to 2 hours of administration. This measurement of how fast the substance reaches peak concentration in the blood (Tmax) indicates the expected speed of systemic distribution.

Q: How long does the effect of one dose of Siroxyl usually last?

A: The duration of the substance's presence in the body is often described by its plasma half-life (Tfrac12). Official information reports that the active ingredient in Siroxyl has a half-life of approximately 1.3 to 2 hours. This measurement reflects the time it takes for the concentration of the substance in the blood to decrease by 50%.

Q: Are there any foods or drinks that interact with Siroxyl?

A: Official product information contains cautions regarding combination with other medicinal products linked to an increased risk of gastrointestinal bleeding or ulceration. Furthermore, it is noted that some liquid formulations of Siroxyl contain ethanol (alcohol) as an inactive excipient. The documentation states the medicine can generally be taken without regard to food.

Q: What should be done if a dose of Siroxyl is missed?

A: Information found in patient information leaflets generally advises that if a dose is missed, it should be taken as soon as it is remembered. However, if the time for the next scheduled dose is approaching, the missed dose should be skipped entirely. Official patient information consistently states that a double dose should not be taken to compensate for a missed dose.

Q: How does Siroxyl interact with common supplements like Vitamin D or Zinc?

A: Official regulatory documents indicate that there are no known or reported interactions involving common metabolic processes, such as those regulated by Cytochrome P450 enzymes. This statement covers many substances, but dedicated regulatory research for specific supplements like Vitamin D or Zinc may be limited. Patients interested in supplement use should consult official product documentation for relevant safety information.

Q: Is Siroxyl generally safe for teenagers to use?

A: Regulatory documents define specific age rules for this medicine. For instance, high-dose granule formulations are generally not considered suitable for children up to 15 years of age. Standard formulations, such as syrup or capsules, are generally available for individuals over the age of 15, subject to official age rules.

Q: What is the typical age range that studies on Siroxyl focus on?

A: Clinical studies have evaluated the substance's effects predominantly in adult populations, including the elderly. The research scope involves chronic respiratory conditions like Chronic Obstructive Pulmonary Disease (COPD), which typically affect older patient groups.

Q: Can Siroxyl affect my ability to drive or operate machinery?

A: Official safety sections for some product licenses indicate that no effects on the ability to drive or operate machinery have been reported. However, regulatory documents note rare side effects such as headache or dizziness, and these types of effects may potentially impact alertness.

Q: Are there known interactions between Siroxyl and grapefruit juice?

A: The official interaction profile reports no known interactions via Cytochrome P450 enzymes, which are the metabolic pathways commonly affected by grapefruit. The product information does not specifically list grapefruit juice as a known interaction, but rather provides general statements on metabolic enzymes.

Q: Does Siroxyl have a sedative effect?

A: Sedation or drowsiness is not commonly listed among the officially reported adverse effects of Siroxyl. When classifying adverse reactions by frequency, the most frequently reported adverse effects in the official documentation involve the gastrointestinal system.

Q: Can taking Siroxyl affect my mood or mental clarity?

A: Officially reported rare side effects include symptoms affecting the central nervous system, such as headache and dizziness. However, official regulatory documents do not explicitly list changes to mood or mental clarity among the known adverse reaction classifications.

How should Siroxyl be stored and disposed of?

How to Store and Dispose of Siroxyl?

The official requirements for the storage and disposal of Siroxyl (carbocysteine) are defined by government regulatory documents to maintain product quality and safety.

Requirement Category Official Regulatory Statement
Temperature and Environment Must be stored at a temperature not exceeding 25 C or 30 C and protected from light and direct heat.
Container and Stability The container must be kept tightly closed. The syrup must be used within one month after first opening (duration may vary by specific license).
Child Safety Mandatory instruction to store the medicine out of the sight and reach of children.
Disposal Unused or expired product must be disposed of in accordance with local requirements and should not be discarded via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Siroxyl found in:

A-Z Index: